Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GB-5001 (IM/SC Donepezil) vs Oral Donepezil in Healthy Males
NCT06127368Phase 1Recruiting
- Sponsor
- G2GBIO
- Start
- Jan 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GB-5001D in Alzheimer's disease (AD), sponsored by G2GBIO. Primary endpoints: Adverse Events, Clinical Laboratory Tests and 3 more. Started Jan 2024; status: recruiting.
02
Drugs
GB-5001D
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06127368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06127368.